Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the extremity, a randomized trial showed. In patients with mostly undifferentiated ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 24, Iovance Biotherapeutics announced positive early data from a pilot ...
Apatinib plus camrelizumab (SHR-1210) for unresectable high-grade osteosarcoma (APFAO) progressing after chemotherapy: A prospective, open label, phase II trial. This is an ASCO Meeting Abstract from ...
Asianet Newsable on MSN
Why did IOVA stock gain pre-market today?
The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, ...
A combination of eribulin (Halaven) and pembrolizumab (Keytruda) offered promising results in patients with metastatic soft tissue sarcomas that were sensitive to immune checkpoint inhibition (ICI), a ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A 56-year-old man presented to the ED with 3 months of ...
Please provide your email address to receive an email when new articles are posted on . A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results